HIM
MCRB icon

Hillhouse Investment Management’s Seres Therapeutics MCRB Stock Holding History

Hillhouse Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,055
Closed -$238K – 62
2017
Q1 		$238K Hold
1,055
– – ﹤0.01% 53
2016
Q4 		$209K Hold
1,055
– – ﹤0.01% 34
2016
Q3 		$259K Buy
+1,055
New +$370K 0.01% 36

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hillhouse Investment Management's MCRB Position: Q2 2017 in Review

Hillhouse Investment Management sold out of Seres Therapeutics (MCRB) in Q2 2017, closing a stake of 1,055 shares — an estimated $238K sold.

Hillhouse Investment Management first reported a position in MCRB in Q3 2016 and held it in 3 quarters. The position peaked at $259K in Q3 2016. 74 funds tracked by Wall St. Rank hold MCRB as of Q2 2017.

  • Hillhouse Investment Management reported no remaining Seres Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Hillhouse Investment Management sold 1,055 Seres Therapeutics shares in Q2 2017, an estimated $238K.
  • Hillhouse Investment Management first reported a position in Seres Therapeutics in Q3 2016 and held it in 3 quarters.
  • Hillhouse Investment Management's Seres Therapeutics position peaked at $259K in Q3 2016.
  • 74 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2017.

Based on Hillhouse Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.